Researchers identify surface protein as a new osteosarcoma therapeutic target for antibody-drug conjugates

(University of Texas M. D. Anderson Cancer Center) A preclinical study shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma tumor cells without damaging normal tissues. This technology, using precision therapy targeting of cell-surface proteins through a Bicycle toxin conjugate (BTC), shows encouraging results for the treatment of osteosarcoma.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news